Canlyniadau Chwilio - Baselga, Josè

Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors gan Toska, Eneda, Baselga, José

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Targeted therapies for breast cancer gan Higgins, Michaela J., Baselga, José

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy gan Scaltriti, Maurizio, Elkabets, Moshe, Baselga, José

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors gan Carracedo, Arkaitz, Baselga, Jose, Pandolfi, Pier Paolo

Cael y testun llawn Cael y testun llawn

Treatment of HER2-Positive Metastatic Breast Cancer gan Swain, Sandra M., Clark, Emma, Baselga, José

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Implementing Genome-Driven Oncology gan Hyman, David M., Taylor, Barry S., Baselga, José

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A view on drug resistance in cancer gan Vasan, Neil, Baselga, José, Hyman, David M.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism gan Fuentes, Gloria, Scaltriti, Maurizio, Baselga, José, Verma, Chandra S

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Advances in the management of HER2-positive early breast cancer gan Baselga, José, Coleman, Robert E., Cortés, Javier, Janni, Wolfgang

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs gan Osmanbeyoglu, Hatice U., Toska, Eneda, Chan, Carmen, Baselga, José, Leslie, Christina S.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Unconventional Secretion is a Major Contributor of Cancer Cell Line Secretomes gan Villarreal, Laura, Méndez, Olga, Salvans, Cándida, Gregori, Josep, Baselga, José, Villanueva, Josep

Cael y testun llawn Cael y testun llawn Cael y testun llawn

The Carboxy-terminal Cysteine of the Tetraspanin L6 Antigen Is Required for Its Interaction with SITAC, a Novel PDZ Protein gan Borrell-Pagès, Maria, Fernández-Larrea, Juan, Borroto, Aldo, Rojo, Federico, Baselga, José, Arribas, Joaquín

Cael y testun llawn Cael y testun llawn

Proteomic Identification of Desmoglein 2 and Activated Leukocyte Cell Adhesion Molecule as Substrates of ADAM17 and ADAM10 by Difference Gel Electrophoresis gan Bech-Serra, Joan J., Santiago-Josefat, Belén, Esselens, Cary, Saftig, Paul, Baselga, José, Arribas, Joaquín, Canals, Francesc

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation gan Anido, Judit, Scaltriti, Maurizio, Bech Serra, Joan Josep, Josefat, Belén Santiago, Rojo Todo, Federico, Baselga, José, Arribas, Joaquín

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance gan Wehrenberg-Klee, Eric, Turker, N. Selcan, Heidari, Pedram, Larimer, Benjamin, Juric, Dejan, Baselga, José, Scaltriti, Maurizio, Mahmood, Umar

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-cont... gan Miles, David, Baselga, José, Amadori, Dino, Sunpaweravong, Patrapim, Semiglazov, Vladimir, Knott, Adam, Clark, Emma, Ross, Graham, Swain, Sandra M.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial gan Bonner, James, Giralt, Jordi, Harari, Paul, Spencer, Sharon, Schulten, Jeltje, Hossain, Anwar, Chang, Shao-Chun, Chin, Steve, Baselga, José

Cael y testun llawn Cael y testun llawn Cael y testun llawn

TARGETING THE MUC1-C ONCOPROTEIN DOWNREGULATES HER2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS gan Raina, Deepak, Uchida, Yasumitsu, Kharbanda, Akriti, Rajabi, Hasan, Panchamoorthy, Govind, Jin, Caining, Kharbanda, Surender, Scaltriti, Maurizio, Baselga, Jose, Kufe, Donald

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer gan Prat, Aleix, Carey, Lisa A., Adamo, Barbara, Vidal, Maria, Tabernero, Josep, Cortés, Javier, Parker, Joel S., Perou, Charles M., Baselga, José

Cael y testun llawn Cael y testun llawn Cael y testun llawn

An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors gan Jonas, Oliver, Landry, Heather M., Fuller, Jason E., Santini, John T., Baselga, Jose, Tepper, Robert I., Cima, Michael J., Langer, Robert

Cael y testun llawn Cael y testun llawn Cael y testun llawn